QUOD Statistics October 2017 NRG(17)28 QUOD Bioresource Key Figures - - PowerPoint PPT Presentation

▶

Mar 12, 2024 153 likes •325 views

QUOD Statistics October 2017 NRG(17)28 QUOD Bioresource Key Figures Da Date te 1 O 1 Octob tober er 20 2017 17 Donor Donors s 2, 2,591 591 Sa Sampl mples es 45, 45,48 486 i 6 in n tot total, al, inc inclu ludin ding:

SLIDE 1

QUOD Statistics

October 2017

NRG(17)28

SLIDE 2

QUOD Bioresource Key Figures

Da Date te 1 O 1 Octob tober er 20 2017 17 Donor Donors s 2, 2,591 591 Sa Sampl mples es 45, 45,48 486 i 6 in n tot total, al, inc inclu ludin ding: g: Bl Blood

24, 24,46 460 s 0 sam ample ples Ur Urine ine 5,6 5,675 s 5 sam ample ples Ki Kidne dney y 6,1 6,197 s 7 sam ample ples s (3,12 ,128 8 bio biopsi psies) s) Li Liver ver 3,4 3,461 s 1 sam ample ples s (1,73 ,739 9 bio biopsi psies) s) Ur Urete eter r 3,7 3,780 s 0 sam ample ples s (1,90 ,903 3 bio biopsi psies) s) Sp Splee leen n 1,9 1,913 s 3 sam ample ples s (1,91 ,913 3 bio biopsi psies) s) Un Units its 271 271,94 ,949 b 9 bio ioban bank i k items ems

NRG(17)28

SLIDE 3

QUOD Donors In Total and Per Region

Milestone: 2,500 donors were enrolled into the QUOD Bioresource by 22 August 2017

NRG(17)28

SLIDE 4

QUOD Samples In Total and Per Type

NRG(17)28

SLIDE 5

QUOD Sample Collection Metrics

NRG(17)28

SLIDE 6

QUOD Biopsy and Incident Metrics

General Incidents:

Clinical incidents – no significant recipient consequences or thought not to be attributable to a QUOD biopsy

Serious Adverse Reactions:

Clinical incidents with recipient consequences – considered as most likely due to a QUOD biopsy

NRG(17)28

SLIDE 7

QUOD Biopsy and Incident Metrics

General Incidents:

Clinical incidents – no significant recipient consequences or thought not to be attributable to a QUOD biopsy

Serious Adverse Reactions:

Clinical incidents with recipient consequences – considered as most likely due to a QUOD biopsy

NRG(17)28

SLIDE 8

QUOD Biopsy and Incident Metrics

General Incidents:

Clinical incidents – no significant recipient consequences or thought not to be attributable to a QUOD biopsy

Serious Adverse Reactions:

Clinical incidents with recipient consequences – considered as most likely due to a QUOD biopsy

NRG(17)28

SLIDE 9

QUOD Biopsy and Incident Metrics

General Incidents:

Clinical incidents – no significant recipient consequences or thought not to be attributable to a QUOD biopsy

Serious Adverse Reactions:

Clinical incidents with recipient consequences – considered as most likely due to a QUOD biopsy

NRG(17)28

SLIDE 10

QUOD Biopsy and Incident Metrics

Literature References:

– Peters et al (2017). Acta Radiol. 58(2):240-8. – Chunduri et al (2015). Semin Dial. 28(2):E11-4. – Furness et al (2003). Transplantation. 76(6):969-73. – Cozens et al (1992). Br J Radiol. 65(775):594-7.

NRG(17)28

SLIDE 11

Consent for QUOD Research and Actual QUOD Donors — Per Month

All Donors (Proc + Non) Cases in Sep ‘17: 84 Tx Consent / Auth 75 Res. Consent / Auth 67 Actual QUOD Donors

NRG(17)28

SLIDE 12

Actual Organ Donors Cases in Sep ‘17: 69 Tx Consent / Auth 61 Res. Consent / Auth 59 Actual QUOD Donors Non–proceeding Donors Cases in Sep ‘17: 15 Tx Consent / Auth 14 Res. Consent / Auth 8 Actual QUOD Donors

NRG(17)28

SLIDE 13

Consent for QUOD Research and Actual QUOD Donors — Step Chart

NRG(17)28

SLIDE 14

Consent for QUOD Research and Actual QUOD Donors — Per SNOD Team

NRG(17)28

SLIDE 15

QUOD Samples Issued to Applications

– Latest issued samples (Sep’17) : RAP028 (Khorsandi), RAP030 (Brennan) – Samples were issued to 14 research applications, as complete or phased sample sets – Issued samples account to 1% of QUOD biobank items, while covering 15% of donors – Further samples will be allocated and issued to 13 approved research applications

NRG(17)28